

Supplementary File 1: Hospital Triage Areas for COVID-19 and clinical algorithm for management of COVID-19 pneumonia



Supplementary File 2: Anticoagulation protocol at our centre based on conventional and POC global coagulation tests.



Supplementary File 3: Baseline characteristics, co-morbidities, and treatment details of the admitted patients with COVID-19.

Parameter	Total Patients (N=74)	Low flow Oxygen Group 1 (n=11)	High flow Oxygen Group 2 (n=34)	Invasive Ventilation Group 3 (n=29)	P value 1 vs. 2	P value 1 vs 3	
Comorbidities							
Hypothyroidism	13(17.6)	0	7(20.6)	6(20.7)	0.101	0.102	
COPD	1(1.4)	0	0	1(3.4)	-	0.725	
Asthma	1(1.4)	0	0	1(3.4)	-	0.725	
Obesity	27(36.48)	2(18.2)	5(14.7)	10(34.5)	0.555	0.315	
Treatment given in each group							
Tocilizumab	32(43)	5(15.6)	17(53.1)	10(31.2)	0.534	0.522	
Remdesivir	23(31)	3(27.3)	7(20.6)	13(44.8)	0.465	0.312	
HCQS	16(22)	3(27.3)	11(33.3)	2(6.9)	0.709	0.117	
Antibiotics	72(97)	10(90.9)	33(97.1)	29(100)	0.390	0.100	
Antifungals	27(36)	0	12(35.3)	15(51.7)	0.021	0.003	

Immuvac (mycobacterium indicus pranii)	31(42)	6(54.5)	19(55.9)	6(20.6)	0.938	0.866
Plasma therapy	2(3)	0	1(3)	1(3)	1	
Steroid duration(days)	6(0-7)	4(3-5)	1(0-5.75)	5(0-7)	0.059	0.873

Abbreviations: COPD, chronic obstructive pulmonary disease; HCQS, hydroxychloroquine

Supplementary File 4: Predictors of Mortality using Cox Proportional Hazards Analysis

Univariate Analysis			Multivariate Analysis		
Covariate	variate HR (95% CI)		HR (95% CI)	P value	
CRP	1.007 (1.005- 1.016)	0.003	1.040 (1.020-1.090)	0.014	
PF	0.540 (0.291-0.901)	0.429	0.901 (0.702- 1.100)	0.045	
HLE	1.020 (1.007-1.034)	0.002	1.010 (1.006- 1.030)	0.025	
PF Ratio	0.989 (0.979- 0.999)	0.038			
Ferritin	1.001 (1.000- 1.010)	0.037			
NLR	1.027 (1.007- 1.047)	0.009			
D-Dimer	1.000 (1.000- 1.000)	0.027			
LDH	1.003 (1.000- 1.000)	0.021			
Bilirubin	1.147 (1.010- 1.303)	0.035			
ACT	1.012(1.004- 1.020)	0.005			
dlhACT	1.033 (1.013- 1.054)	0.001			
d1hCR	0.956 (0.908- 1.006)	0.081			
d1h Peak amplitude	0.960 (0.920- 1.002)	0.062			
D1gbACT	1.022 (1.011- 1.033)	0.000			
D1gb Peak- Amplitude	0.948 (0.898-1.000)	0.051			

Abbreviations: ACT, activated clotting clotting time; CRP, C Reactive Protein; CR, clot rate; LDH, lactate dehydrogenase; PF, platelet function; HLE, heparin like effect; NLR, neutrophil lymphocyte ratio; hACT,

heparinase treated; hCR, heparinase treated CR; hPF, heparinase treated platelet function; PF Ratio, PaO_2/FiO_2 ratio;

Supplementary File 5: Predictors for mortality in COVID 19 patients based on Receiver Operating Characteristics (ROC) analysis

Parameter	Cut off value	AUC	Sensitivity	Specificity	P value
CRP	96·7 mg/l	0.767	87.5	69	0.001
Ferritin	587 ng/ml	0.690	75	61	0.021
LDH	405 U/L	0.700	75	70	0.015
CR	27.5	0.761	66.7	87	0.012
	units/min				
ACT	131 seconds	0.744	60	80	0021
D1hPeak-amp	72⋅5 units	0.736	81.8	65	0.029
D1gbACT	158 seconds	0.893	91.7	79	0.001
D1gbCR	27 units/min	0.730	63.7	79	0.027
gbPA	67⋅5 units	0.746	72.7	73	0.023

Abbreviations: CRP, C Reactive Protein; ACT – Activated Clotting Time, CR – Clot Rate, PF – Platelet Function; PA, peak amplitude; LDH, lactate dehydrogenase·